Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Dacomitinib in Indian Patients with EGFR+ Metastatic NSCLC
NCT04511533Phase 4Completed
- Sponsor
- Pfizer
- Start
- Aug 2020
- Primary completion
- Oct 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dacomitinib, sponsored by Pfizer. Started Aug 2020; status: completed.
02
Drugs
dacomitinib
Beyond the preview
Go deeper on NCT04511533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511533.